TheEdgeResearch
Home / Stocks / COYA

Coya Therapeutics, Inc. (COYA)

NASDAQ Healthcare Biotechnology
$2.95 ▼ -1.01%
Market Cap
$69.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.58
52-Wk Range
2.72-6.62
CEO
Arun Swaminathan
Country
US
Currency
USD

Coya Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Houston, TX, US. The stock last traded at $2.95, down 1.01% on the session, giving a market capitalisation of $69.2M. On trailing twelve-month figures it carries a trailing P/E of -2.12, a net margin of -643.5%. Its beta of 0.58 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-2.12
Price / Sales
14.76
Price / Book
2.06
EV / EBITDA
-1.09
Gross margin
100.0%
Operating margin
-675.3%
Net margin
-643.5%
Return on equity
—
Debt / equity
0.00
Current ratio
7.24
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
8
IPO date
2022-12-29
Headquarters
Houston, TX, US
About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

Comparable companies

Coya Therapeutics, Inc. is most often compared with the following Healthcare names:

CLNNCNTXIMMXMGNXORMPOVIDPLRXSTTKWHWKZNTL
More research on COYA
COYA technical analysis COYA TheEdge Score Compare against peers
Open full interactive analysis & DCF →